229 related articles for article (PubMed ID: 32585229)
21. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
22. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
23. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.
Reinhardt J; Landsberg J; Schmid-Burgk JL; Ramis BB; Bald T; Glodde N; Lopez-Ramos D; Young A; Ngiow SF; Nettersheim D; Schorle H; Quast T; Kolanus W; Schadendorf D; Long GV; Madore J; Scolyer RA; Ribas A; Smyth MJ; Tumeh PC; Tüting T; Hölzel M
Cancer Res; 2017 Sep; 77(17):4697-4709. PubMed ID: 28652246
[TBL] [Abstract][Full Text] [Related]
24. Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target.
Yang J; Liao X; Yu J; Zhou P
Curr Med Chem; 2018; 25(19):2260-2271. PubMed ID: 29345574
[TBL] [Abstract][Full Text] [Related]
25. Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.
Young A; Ngiow SF; Madore J; Reinhardt J; Landsberg J; Chitsazan A; Rautela J; Bald T; Barkauskas DS; Ahern E; Huntington ND; Schadendorf D; Long GV; Boyle GM; Hölzel M; Scolyer RA; Smyth MJ
Cancer Res; 2017 Sep; 77(17):4684-4696. PubMed ID: 28652244
[TBL] [Abstract][Full Text] [Related]
26. Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration.
Koszałka P; Gołuńska M; Urban A; Stasiłojć G; Stanisławowski M; Majewski M; Składanowski AC; Bigda J
PLoS One; 2016; 11(3):e0151420. PubMed ID: 26964090
[TBL] [Abstract][Full Text] [Related]
27. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
28. Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface.
Rahimova R; Fontanel S; Lionne C; Jordheim LP; Peyrottes S; Chaloin L
PLoS Comput Biol; 2018 Jan; 14(1):e1005943. PubMed ID: 29377887
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.
Gong YP; Wan RZ; Liu ZP
Expert Opin Ther Pat; 2018 Feb; 28(2):167-171. PubMed ID: 29166791
[TBL] [Abstract][Full Text] [Related]
30. Extracellular adenosine produced by ecto-5'-nucleotidase (CD73) regulates macrophage pro-inflammatory responses, nitric oxide production, and favors Salmonella persistence.
Costales MG; Alam MS; Cavanaugh C; Williams KM
Nitric Oxide; 2018 Jan; 72():7-15. PubMed ID: 29108754
[TBL] [Abstract][Full Text] [Related]
31. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.
Turiello R; Capone M; Morretta E; Monti MC; Madonna G; Azzaro R; Del Gaudio P; Simeone E; Sorrentino A; Ascierto PA; Morello S
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35273100
[TBL] [Abstract][Full Text] [Related]
32. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
[TBL] [Abstract][Full Text] [Related]
33. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
[TBL] [Abstract][Full Text] [Related]
34. A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation.
Morandi F; Morandi B; Horenstein AL; Chillemi A; Quarona V; Zaccarello G; Carrega P; Ferlazzo G; Mingari MC; Moretta L; Pistoia V; Malavasi F
Oncotarget; 2015 Sep; 6(28):25602-18. PubMed ID: 26329660
[TBL] [Abstract][Full Text] [Related]
35. CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling.
Meng F; Guo Z; Hu Y; Mai W; Zhang Z; Zhang B; Ge Q; Lou H; Guo F; Chen J; Duan S; Gao Z
Brain; 2019 Mar; 142(3):700-718. PubMed ID: 30689733
[TBL] [Abstract][Full Text] [Related]
36. Targeting cancer-derived adenosine: new therapeutic approaches.
Young A; Mittal D; Stagg J; Smyth MJ
Cancer Discov; 2014 Aug; 4(8):879-88. PubMed ID: 25035124
[TBL] [Abstract][Full Text] [Related]
37. Host surface ectonucleotidase-CD73 and the opportunistic pathogen,
Lee JS; Chowdhury N; Roberts JS; Yilmaz Ö
Virulence; 2020 Dec; 11(1):414-429. PubMed ID: 32419582
[TBL] [Abstract][Full Text] [Related]
38. Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.
Beatty JW; Lindsey EA; Thomas-Tran R; Debien L; Mandal D; Jeffrey JL; Tran AT; Fournier J; Jacob SD; Yan X; Drew SL; Ginn E; Chen A; Pham AT; Zhao S; Jin L; Young SW; Walker NP; Leleti MR; Moschütz S; Sträter N; Powers JP; Lawson KV
J Med Chem; 2020 Apr; 63(8):3935-3955. PubMed ID: 32212732
[TBL] [Abstract][Full Text] [Related]
39. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present).
Nocentini A; Capasso C; Supuran CT
Expert Opin Ther Pat; 2021 Oct; 31(10):867-876. PubMed ID: 33909515
[TBL] [Abstract][Full Text] [Related]
40. CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis.
Koszałka P; Gołuńska M; Stanisławowski M; Urban A; Stasiłojć G; Majewski M; Wierzbicki P; Składanowski AC; Bigda J
Int J Biochem Cell Biol; 2015 Dec; 69():1-10. PubMed ID: 26545615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
